Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients
Clinical and Experimental Hepatology · 2021 · 7 (3) · 320-327
DOI: 10.5114/ceh.2021.109293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Hepatology, 2021. Verfasst von Eman Rewisha und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Egypt. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
INTRODUCTION: Fibrosis is an inevitable complication of chronic hepatitis C virus (HCV) infection. Direct acting antivirals (DAAs) radically treated HCV and were suggested to ameliorate fibrosis. Silymarin (a natural herbal remedy) was proposed to further decrease hepatic inflammation and fibrosis. Consequently, serial monitoring of liver fibrosis status by different biomarkers is needed. AIM OF THE STUDY: To assess hyaluronic acid (HA) as a potential marker of fibrosis regression after DAAs in chronic HCV patients; in addition, to evaluate silymarin as an agent that, beside DAAs, could further improve fibrosis. MATERIAL AND METHODS: Two groups were included (150 patients each). Group 1 received DAAs only, while group 2 received DAAs followed by silymarin. Hyaluronic acid and FIB4 score were assessed at baseline before treatment and 1 year after inclusion in the study. RESULTS: We found that DAA therapy alone or in combination with silymarin resulted in a significant reduction in serum HA level. However, the latter case showed a statistically significantly greater reduction (p = 0.034). Mean ±SD of serum HA level was 211.8 ±179.9 and 143.3 ±123.9 µg/l before and one year after inclusion respectively in group 1 (p = 0.001) and also, its level decreased significantly in group 2 from 188.3 ±211.8 µg/l before receiving DAAs to 126.4 ±136.9 µg/l at one year after inclusion (p = 0.001). There was no significant difference between the 2 studied groups as regards FIB-4 at 1 year after inclusion (p = 0.103). CONCLUSIONS: Hyaluronic acid might be a sensitive marker for monitoring fibrosis regression in treated chronic HCV patients. Adding silymarin to treatment protocols could ameliorate the fibrosis status.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Egypt.
- Clinical Pathology Department, National Liver Institute, Menoufia University, Egypt.
Zitieren
APA
Rewisha, E., Salman, T., Alhaddad, O., Raia, G. A., Naguib, M., Rashad, S., Abdelfattah, A., Metwally, K., & Abdelsameea, E. (2021). Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients. Clinical and Experimental Hepatology, 7(3), 320-327. https://doi.org/10.5114/ceh.2021.109293
Vancouver
Rewisha E, Salman T, Alhaddad O, Raia GA, Naguib M, Rashad S, et al. Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients. Clinical and Experimental Hepatology. 2021;7(3):320-327. doi:10.5114/ceh.2021.109293
BibTeX
@article{Rewisha2021,
author = {Rewisha, Eman and Salman, Tary and Alhaddad, Omkolsoum and Raia, Gamal Abo and Naguib, Mary and Rashad, Shymaa and Abdelfattah, Ahmed and Metwally, Khaled and Abdelsameea, Eman},
title = {Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients},
journal = {Clinical and Experimental Hepatology},
year = {2021},
volume = {7},
number = {3},
pages = {320--327},
doi = {10.5114/ceh.2021.109293}
}
EUVIMED